Home/LENZ Therapeutics/Kris Gambelin

KG

Kris Gambelin

SVP, Regulatory and Clinical Operations

LENZ Therapeutics

Therapeutic Areas

Ophthalmology Refractive Disorders

LENZ Therapeutics Pipeline

Drug	Indication	Phase
VIZZ™ (aceclidine ophthalmic solution) 1.44%	Presbyopia	Approved
LNZ101 (aceclidine/brimonidine)	Presbyopia	Phase 3

Leadership Team at LENZ Therapeutics

Eef Schimmelpennink

President and Chief Executive Officer

Chief Financial Officer

Chief Commercial Officer

Chief Medical Officer

View full LENZ Therapeutics profile